TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29383895

Group type: EXPERIMENTAL
Intervention: Deqi-expectation (DE) group, n=15
Number of subjects: 64

Group type: COMPARATOR
Intervention: No-deqi-expectation (NDE) group, n=49
Number of subjects: 64
Study: 27702747

Group type: EXPERIMENTAL
Intervention: sitting > 14 h/day with hypercaloric energy balance (SH)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: sitting > 14 h/day with net energy balance (SB)
Number of subjects: 7

Group type: COMPARATOR
Intervention: active walking/standing with net energy balance (WB)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: acute exercise after prolonged sitting (SH and SB)
Number of subjects: 7
Study: 24500611

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate vegan diet
Number of subjects: 39

Group type: COMPARATOR
Intervention: High-carbohydrate lacto-ovo vegetarian diet
Number of subjects: 39
Study: 22669333

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate/high-fat diet (LC/HFD) for 3 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal diet (ND) for 3 days
Number of subjects: 9
Study: 19777316

Group type: EXPERIMENTAL
Intervention: Proximally porous-coated tapered cementless femoral component
Number of subjects: 388

Group type: COMPARATOR
Intervention: Fully porous-coated cementless femoral component
Number of subjects: 388
Study: 18036446

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 1748

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 1748
Study: 15734868

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (n = 5)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Troglitazone (n = 3)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rosiglitazone and Troglitazone
Number of subjects: 8
Study: 14522725

Group type: EXPERIMENTAL
Intervention: High physical activity (HPA) treatment with an energy expenditure (EE) goal of 2500 kcal/wk
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard behavior therapy (SBT) for obesity with an EE goal of 1000 kcal/wk
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: High physical activity (HPA) treatment
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard behavior therapy (SBT) for obesity
Number of subjects: 202
Study: 10098761

Group type: EXPERIMENTAL
Intervention: Screening arm (PSA screening)
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 20000
Study: 8679367

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway removed while anaesthetized
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laryngeal mask airway removed on awakening
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 2068774

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 1625

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 1625
Study: 6642873

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral stress management training (3 hours individual training)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (experienced nurses)
Number of subjects: 14
Study: 31601587

Group type: EXPERIMENTAL
Intervention: Multicomponent self-management intervention for opioid tapering
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group attendance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative data from interviews and feedback forms
Number of subjects: 0
Study: 29792425

Group type: EXPERIMENTAL
Intervention: Roasted barley extract (RBE)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Roasted barley extract (RBE) in cold-feeling subjects
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo in cold-feeling subjects
Number of subjects: 15
Study: 26942358

Group type: EXPERIMENTAL
Intervention: Quickstart group (etonogestrel implants with mifepristone)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Afterstart group (etonogestrel implants after abortion)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Quickstart group
Number of subjects: 476

Group type: COMPARATOR
Intervention: Afterstart group
Number of subjects: 476
Study: 25122041

Group type: EXPERIMENTAL
Intervention: tizanidine 4 mg
Number of subjects: 114

Group type: COMPARATOR
Intervention: baseline
Number of subjects: 114

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 114
Study: 22997780

Group type: EXPERIMENTAL
Intervention: Head-point group (penetrating acupuncture)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medication group (Sodium Nitroprusside, Mannite, etc.)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Head-point group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medication group
Number of subjects: 60
Study: 20589591

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia group (IHG)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 11
Study: 17483139

Group type: EXPERIMENTAL
Intervention: Weekly support
Number of subjects: 925

Group type: COMPARATOR
Intervention: Basic support
Number of subjects: 925
Study: 16350718

Group type: EXPERIMENTAL
Intervention: VEGF concentrations in patients with benign and malignant thyroid tumors
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Soluble VEGF receptor concentrations in patients with benign and malignant thyroid tumors
Number of subjects: 45

Group type: COMPARATOR
Intervention: Comparison with control group (healthy individuals)
Number of subjects: 45
Study: 12101195

Group type: EXPERIMENTAL
Intervention: 12 weeks of neoadjuvant hormonal treatment (NHT)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: 24 weeks of neoadjuvant hormonal treatment (NHT)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Preoperative NHT (12 and 24 weeks)
Number of subjects: 393
Study: 10438352

Group type: EXPERIMENTAL
Intervention: Indinavir, zidovudine, and lamivudine (triple therapy)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Indinavir (single therapy)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Zidovudine and lamivudine (two-drug therapy)
Number of subjects: 320
Study: 7783254

Group type: EXPERIMENTAL
Intervention: 30% FC‐23
Number of subjects: 5

Group type: COMPARATOR
Intervention: 40% nitrous oxide
Number of subjects: 5

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 60% FC‐23
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 40% FC‐23
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 30% FC‐23 during NMR imaging
Number of subjects: 5
Study: 2370328

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate cream applied for 0.5 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate cream applied for 1.0 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate cream applied for 1.5 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate cream applied for 16.0 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.05% fluocinonide cream applied for 16 hours
Number of subjects: 0
Study: 377153

Group type: EXPERIMENTAL
Intervention: Metronidazole (Flagyl)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30706535

Group type: EXPERIMENTAL
Intervention: Three Dimensions for Diabetes (3DFD) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 31562151

Group type: EXPERIMENTAL
Intervention: Educational inequalities in self-rated health (SRH)
Number of subjects: 54197

Group type: EXPERIMENTAL
Intervention: Income inequalities in self-rated health (SRH)
Number of subjects: 54197

Group type: EXPERIMENTAL
Intervention: Relative indices of inequality (RII) by education
Number of subjects: 54197

Group type: EXPERIMENTAL
Intervention: Relative indices of inequality (RII) by income
Number of subjects: 54197
Study: 29172680

Group type: EXPERIMENTAL
Intervention: DR/ER-MPH (40-80 mg/day)
Number of subjects: 161
Study: 24997071

Group type: EXPERIMENTAL
Intervention: Family Assessment Response (FAR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Investigation Response (IR)
Number of subjects: 0
Study: 24798277

Group type: EXPERIMENTAL
Intervention: Rifalazil (25 mg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Azithromycin (1 g)
Number of subjects: 82
Study: 21946903

Group type: EXPERIMENTAL
Intervention: Survivors using hot flash treatments
Number of subjects: 237

Group type: COMPARATOR
Intervention: Midlife women using hot flash treatments
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 237

Group type: COMPARATOR
Intervention: Midlife women
Number of subjects: 237
Study: 19651710

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Vigabatrin (among subjects with prestudy alcohol use)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (among subjects with prestudy alcohol use)
Number of subjects: 103
Study: 17599440

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SESs)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Bare metal stents (BMSs)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Overlapping SESs
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nonoverlapping SES segments
Number of subjects: 75
Study: 15162364

Group type: EXPERIMENTAL
Intervention: Kava extract WS 1490 (150 mg per day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 12240460

Group type: EXPERIMENTAL
Intervention: Knowledge translation interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic reviews of the literature
Number of subjects: 0
Study: 10194235

Group type: EXPERIMENTAL
Intervention: Ganciclovir implant plus oral ganciclovir (4.5 g daily)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Ganciclovir implant plus oral placebo
Number of subjects: 377

Group type: COMPARATOR
Intervention: Intravenous ganciclovir alone
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir or intravenous ganciclovir
Number of subjects: 377
Study: 7582042

Group type: EXPERIMENTAL
Intervention: Symptomatic treatment studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventions for noncognitive or behavioral symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical approaches to slow disease progression
Number of subjects: 0
Study: 2253196

Group type: EXPERIMENTAL
Intervention: Combination of rhIL-2 (1 x 10(6) units/m2 i.v. over 6 h on days 1-5 and 8-12) and R24 (1 mg/m2 daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of rhIL-2 (1 x 10(6) units/m2 i.v. over 6 h on days 1-5 and 8-12) and R24 (3 mg/m2 daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of rhIL-2 (1 x 10(6) units/m2 i.v. over 6 h on days 1-5 and 8-12) and R24 (8 mg/m2 daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of rhIL-2 (1 x 10(6) units/m2 i.v. over 6 h on days 1-5 and 8-12) and R24 (12 mg/m2 daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of rhIL-2 and R24
Number of subjects: 20
Study: 7114512

Group type: EXPERIMENTAL
Intervention: Nicergoline (0.3 mg/kg bolus, 0.8 mg/kg/h maintenance)
Number of subjects: 43
Study: 31619358

Group type: EXPERIMENTAL
Intervention: Small-Incision Lenticule Extraction (SMILE)
Number of subjects: 70

Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 70
Study: 30933867

Group type: EXPERIMENTAL
Intervention: Snoezelen multisensory environment treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (without treatment)
Number of subjects: 40
Study: 27768397

Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation (0.3 g・kg‐1・d‐1 for 5 days followed by 0.1 g・kg‐1・d‐1 for 23 days; n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (PLA; n = 8)
Number of subjects: 17
Study: 26375599

Group type: EXPERIMENTAL
Intervention: Methylene blue-mediated photodynamic inactivation followed by low-laser therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Miconazole gel
Number of subjects: 40
Study: 25086636

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Trastuzumab or Lapatinib
Number of subjects: 127
Study: 23038944

Group type: EXPERIMENTAL
Intervention: PAPM intervention group
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Conventional instruction intervention group
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 254
Study: 19944914

Group type: EXPERIMENTAL
Intervention: Culturally and linguistically adapted physical activity intervention (Seamos Activas)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Wellness contact control condition
Number of subjects: 93
Study: 17244786

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15346841

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (Group 2)
Number of subjects: 131

Group type: COMPARATOR
Intervention: No thrombus aspiration (Group 1)
Number of subjects: 131
Study: 11602217

Group type: EXPERIMENTAL
Intervention: Anger induced by harassment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opportunity to express anger
Number of subjects: 0

Group type: COMPARATOR
Intervention: No opportunity to express anger
Number of subjects: 0
Study: 11706524

Group type: EXPERIMENTAL
Intervention: Flutamide (FLU) administered for 2 weeks before LH-RHa
Number of subjects: 24

Group type: COMPARATOR
Intervention: No pretreatment (Control group)
Number of subjects: 24
Study: 9150581

Group type: EXPERIMENTAL
Intervention: Participants induced to feel sad
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants not induced to feel sad
Number of subjects: 0
Study: 7970483

Group type: COMPARATOR
Intervention: Conjugated estrogens (0.625 mg/day) alone
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg/day) + MPA (2.5 mg/day continuously)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg/day) + MPA (5.0 mg/day continuously)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg/day) + MPA (5.0 mg/day for last 14 days of each cycle)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg/day) + MPA (10.0 mg/day for last 14 days of each cycle)
Number of subjects: 525
Study: 3591644

Group type: EXPERIMENTAL
Intervention: LIGHT
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: SCBA
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: FF
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CHEM
Number of subjects: 9
Study: 1960555

Group type: EXPERIMENTAL
Intervention: Adriamycin followed by CMF
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMF/Adriamycin
Number of subjects: 0
Study: 1105487

Group type: EXPERIMENTAL
Intervention: prazosin alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: prazosin plus one or more other antihypertensive drugs
Number of subjects: 24
Study: 28768617

Group type: EXPERIMENTAL
Intervention: Physically enhanced environment
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard environment
Number of subjects: 103

Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 103
Study: 27746370

Group type: EXPERIMENTAL
Intervention: Capsaicin 8% patch
Number of subjects: 369

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 369
Study: 27667379

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 18000

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18000
Study: 24880778

Group type: EXPERIMENTAL
Intervention: Thoracic thrust manipulation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Thoracic non-thrust mobilization
Number of subjects: 52
Study: 21822907

Group type: EXPERIMENTAL
Intervention: OTRa (Atosiban tractocide) 7.5 mg intravenous, administered 2 days after embryo transfer.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no OTRa administration).
Number of subjects: 26
Study: 19875041

Group type: EXPERIMENTAL
Intervention: Summative index (SI) of guideline adherence for acute pain management
Number of subjects: 0
Study: 17635851

Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg/d) administered at bedtime
Number of subjects: 215

Group type: COMPARATOR
Intervention: Telmisartan (80 mg/d) administered on awakening
Number of subjects: 215
Study: 14693607

Group type: EXPERIMENTAL
Intervention: Rofecoxib oral suspension 25 mg (Group B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rofecoxib oral suspension 50 mg (Group C)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo oral suspension (Group A)
Number of subjects: 48
Study: 12491077

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (JCOG 8801 study)
Number of subjects: 555
Study: 9832295

Group type: COMPARATOR
Intervention: Compression treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Horse chestnut seed extract (HCSE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8581790

Group type: EXPERIMENTAL
Intervention: Weight loss interventions (specifics not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 2223157

Group type: EXPERIMENTAL
Intervention: Bestatin treatment in squamous cell carcinoma
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (no bestatin) in squamous cell carcinoma
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Bestatin treatment in adenocarcinoma
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (no bestatin) in adenocarcinoma
Number of subjects: 153
Study: 349961

Group type: EXPERIMENTAL
Intervention: Proteinase inhibiting agents and glucagon
Number of subjects: 103

Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 103
Study: 30347523

Group type: EXPERIMENTAL
Intervention: Tuebingen's Sectio Chirurgica (TSC) video
Number of subjects: 114

Group type: COMPARATOR
Intervention: Traditional lecture video
Number of subjects: 114
Study: 28463522

Group type: EXPERIMENTAL
Intervention: Group A (30% CM first bolus, 70% CM second bolus)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Group B (70% CM first bolus, 30% CM second bolus)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Group C (50% CM first bolus, 50% CM second bolus)
Number of subjects: 192

Group type: COMPARATOR
Intervention: All groups (A, B, C) with different imaging delays
Number of subjects: 192
Study: 26163604

Group type: EXPERIMENTAL
Intervention: Distant Reiki (5 sessions, 30 min each night)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual medical and nursing care (Control)
Number of subjects: 100
Study: 23665370

Group type: EXPERIMENTAL
Intervention: Endurance exercise training (ET) for 16 weeks (walking, arm and leg ergometry, n = 32)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Attention control (CT) for 16 weeks (n = 31)
Number of subjects: 63
Study: 21334033

Group type: EXPERIMENTAL
Intervention: Oral beta-blockers
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous beta-blockers
Number of subjects: 40
Study: 19831159

Group type: EXPERIMENTAL
Intervention: Home-based aerobic and progressive resistance exercise intervention
Number of subjects: 38

Group type: COMPARATOR
Intervention: No exercise (Control)
Number of subjects: 38
Study: 17721096

Group type: EXPERIMENTAL
Intervention: Interleukin-2 therapy (subcutaneous IL-2, median of ten 5-day cycles)
Number of subjects: 131
Study: 14994390

Group type: EXPERIMENTAL
Intervention: Etodolac (300 or 1000 mg daily)
Number of subjects: 1433

Group type: EXPERIMENTAL
Intervention: Ibuprofen (2400 mg daily)
Number of subjects: 1433

Group type: COMPARATOR
Intervention: Control group (non-DMARD treatment)
Number of subjects: 1433
Study: 11773161

Group type: EXPERIMENTAL
Intervention: IL-2 plus histamine (1.0 mg bid SC days 1 to 5, weeks 1 to 4)
Number of subjects: 305

Group type: COMPARATOR
Intervention: IL-2 alone (9 MIU/m(2) bid SC on days 1 to 2 of weeks 1 and 3, and 2 MIU/m(2) bid SC on days 1 to 5 of weeks 2 and 4)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: IL-2 plus histamine
Number of subjects: 305
Study: 9872184

Group type: EXPERIMENTAL
Intervention: Supraclavicular lymph node involvement (SCLN)
Number of subjects: 1370

Group type: COMPARATOR
Intervention: Limited forms without SCLN
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Limited forms with SCLN
Number of subjects: 1370

Group type: COMPARATOR
Intervention: Extensive forms without SCLN
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Extensive forms with SCLN
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Overall survival rates
Number of subjects: 1370
Study: 7648827

Group type: EXPERIMENTAL
Intervention: Intravenous insulin (1.8U over 15 min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous insulin (1.8U over 15 min, extended over 30 min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous insulin (3.6U over 60 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no supplementary insulin)
Number of subjects: 10
Study: 2520792

Group type: EXPERIMENTAL
Intervention: Suprapubic catheter (SPC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Transurethral catheter (TUC)
Number of subjects: 90
Study: 1131130

Group type: EXPERIMENTAL
Intervention: Isometric exercise (21% of max leg extension force for 1 min followed by 1-min rest) during bedrest periods.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Isotonic exercise (68% of max VO2) for 0.5 hours in the morning and afternoon during bedrest periods.
Number of subjects: 7

Group type: COMPARATOR
Intervention: No exercise during the third bedrest period.
Number of subjects: 7

Group type: COMPARATOR
Intervention: Ambulatory control period (exercise on a bicycle ergometer at 50% of max VO2 for 1 h/d).
Number of subjects: 7
Study: 30442551

Group type: EXPERIMENTAL
Intervention: Midazolam 15mg (oral)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Auriculotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo tablet (oral) and sham auriculotherapy
Number of subjects: 30